Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells

References

• Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598–5606. doi:10.3748/wjg.v19.i34.5598
   PubMed Web of Science ®Google Scholar
• Wong MCS, Hamilton W, Whiteman DC, et al. Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. Sci Rep. 2018;8(1):4522. doi:10.1038/s41598-018-19819-8
   PubMedGoogle Scholar
• Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–1146. doi:10.1111/jgh.13289
   PubMed Web of Science ®Google Scholar
• Gaur P, Kim MP, Dunkin BJ. Esophageal cancer: recent advances in screening, targeted therapy, and management. J Carcinog. 2014;13(1):11. doi:10.4103/1477-3163.143720
   PubMedGoogle Scholar
• Abdo J, Agrawal DK, Mittal SK. Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther. 2017;17(1):33–45. doi:10.1080/14737140.2017.1260449
   PubMed Web of Science ®Google Scholar
• Maag JLV, Fisher OM, Levert-Mignon A, et al. Novel aberrations uncovered in barrett’s esophagus and esophageal adenocarcinoma using whole transcriptome sequencing. Mol Cancer Res. 2017;15(11):1558–1569. doi:10.1158/1541-7786.MCR-17-0332
   PubMed Web of Science ®Google Scholar
• Secrier M, Li X, de Silva N, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016;48(10):1131–1141. doi:10.1038/ng.3659
   PubMed Web of Science ®Google Scholar
• Frankell AM, Jammula S, Li X, et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet. 2019;51(3):506–516. doi:10.1038/s41588-018-0331-5
   PubMed Web of Science ®Google Scholar
• Labots M, van der Mijn JC, Beekhof R, et al. Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. J Proteomics. 2017;162:99–107. doi:10.1016/j.jprot.2017.04.014
   PubMed Web of Science ®Google Scholar
• Lim YP. Mining the tumor phosphoproteome for cancer markers. Clin Cancer Res. 2005;11(9):3163–3169. doi:10.1158/1078-0432.CCR-04-2243
   PubMed Web of Science ®Google Scholar
• Carter AM, Tan C, Pozo K, et al. Phosphoprotein-based biomarkers as predictors for cancer therapy. Proc Natl Acad Sci U S A. 2020;117(31):18401–18411. doi:10.1073/pnas.2010103117
   PubMed Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. doi:10.1186/s12943-018-0782-4
   PubMed Web of Science ®Google Scholar
• Drake JM, Graham NA, Stoyanova T, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012;109(5):1643–1648. doi:10.1073/pnas.1120985109
   PubMed Web of Science ®Google Scholar
• Andrechek ER, Muller WJ. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2000;2(3):211–216. doi:10.1186/bcr56
   PubMed Web of Science ®Google Scholar
• Silva JM, McMahon M. The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp. 2014;(84):e51149. doi:10.3791/51149
   PubMed Web of Science ®Google Scholar
• Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986;31(4):229–234. doi:10.1002/jso.2930310402
   PubMed Web of Science ®Google Scholar
• Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148–154. doi:10.1007/BF00300234
   PubMed Web of Science ®Google Scholar
• Li YT, Qian XJ, Yu Y, et al. EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy. Oncotarget. 2015;6(19):17491–17500. doi:10.18632/oncotarget.3959
   PubMedGoogle Scholar
• Eskens FA, Mom CH, Planting AS, et al. A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80–85. doi:10.1038/sj.bjc.6604108
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702–4711. doi:10.1038/onc.2008.109
   PubMed Web of Science ®Google Scholar
• Kim H, Gillis LC, Jarvis JD, et al. Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events. BMC Cancer. 2011;11(1):528. doi:10.1186/1471-2407-11-528
   PubMedGoogle Scholar
• Costa R, Carneiro BA, Taxter T, et al. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016;7(34):55924–55938. doi:10.18632/oncotarget.10482
   PubMedGoogle Scholar
• Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12(1):27–37. doi:10.1016/s1097-2765(03)00274-0
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556–2568. doi:10.1200/JCO.2005.07.799
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13):3908–3914. doi:10.1158/1078-0432.CCR-06-0462
   PubMed Web of Science ®Google Scholar
• How J, Mann J, Laczniak AN, Baggstrom MQ. Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature. Clin Lung Cancer. 2017;18(4):354–363. doi:10.1016/j.cllc.2017.01.013
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124–136. doi:10.1200/JCO.19.01154
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589. doi:10.1016/S1470-2045(16)30033-X
   PubMed Web of Science ®Google Scholar
• Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X. Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med. 2015;19(12):2691–2701. doi:10.1111/jcmm.12662
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(1Suppl 1):S53–S67.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Pedraza AM, Cotari J, et al. EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines. Sci Rep. 2017;7(1):9043. doi:10.1038/s41598-017-08940-9
   PubMedGoogle Scholar
• Fleming TP, Saxena A, Clark WC, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 1992;52(16):4550–4553.
   PubMed Web of Science ®Google Scholar
• Sun T, Aceto N, Meerbrey KL, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011;144(5):703–718. doi:10.1016/j.cell.2011.02.003
   PubMed Web of Science ®Google Scholar
• Diamantopoulou Z, Kitsou P, Menashi S, Courty J, Katsoris P. Loss of receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ) promotes prostate cancer metastasis. J Biol Chem. 2012;287(48):40339–40349. doi:10.1074/jbc.M112.405852
   PubMed Web of Science ®Google Scholar
• Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther. 2016;9:5461–5473. doi:10.2147/OTT.S94745
   PubMed Web of Science ®Google Scholar
• Landi L, Tiseo M, Chiari R, et al. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Clin Lung Cancer. 2014;15(6):411–417.e4. doi:10.1016/j.cllc.2014.07.002
   PubMed Web of Science ®Google Scholar
• Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005;23(1):94–101. doi:10.1038/nbt1046
   PubMed Web of Science ®Google Scholar
• Li H, Ren Z, Kang X, et al. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer. 2009;9:366. doi:10.1186/1471-2407-9-366
   Web of Science ®Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. doi:10.1056/NEJMoa1916623
   PubMed Web of Science ®Google Scholar
• Wei Y, Zou Z, Becker N, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013;154(6):1269–1284. doi:10.1016/j.cell.2013.08.015
   PubMed Web of Science ®Google Scholar
• D’Errico G, Alonso-Nocelo M, Vallespinos M, et al. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Oncogene. 2019;38(27):5469–5485. doi:10.1038/s41388-019-0803-9
   PubMed Web of Science ®Google Scholar
• Girnun GD, Chen L, Silvaggi J, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res. 2008;14(20):6478–6486. doi:10.1158/1078-0432.CCR-08-1128
   PubMed Web of Science ®Google Scholar
• Sun T, Yang Q. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. Oncol Lett. 2020;20(1):420–430. doi:10.3892/ol.2020.11562
   PubMed Web of Science ®Google Scholar
• Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008;25(8):843–854. doi:10.1007/s10585-008-9200-4
   PubMed Web of Science ®Google Scholar
• Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14(11):747–753. doi:10.1038/nrc3819
   PubMed Web of Science ®Google Scholar